- Agreement Leverages Company’s Ability for Intramuscular Delivery of LNP-Encapsulated LinearDNA-based Therapies for Veterinary Therapeutic and Prophylactic Applications -
STONY BROOK, N.Y. & ITHICA, N.Y., September 08, 2022--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (‘Applied DNA’ or the "Company"), a leader in polymerase chain reaction ("PCR")-based technologies, and the Cornell University College of Veterinary Medicine ("CUCVM") announced the signing of a research agreement (the "Agreement") to advance LinearDNA™-based vaccine research and discovery for animal diseases with agricultural biosecurity implications. Primarily, the Agreement seeks to combine LinearDNA as a platform for rapid drug development with CUCVM’s expertise in viral vector design to advance a differentiated approach to animal vaccine development for infectious diseases.
The Agreement builds on the strong, existing collaboration between Applied DNA’s biotherapeutics subsidiary, LineaRx, and Dr. Diego Diel, D.V.M, M.S., PhD., Associate Professor of Virology at the Cornell University College of Veterinary Medicine’s Department of Population Medicine and Diagnostics. Dr. Diel is the lead investigator for veterinary clinical trials sponsored by the Company for the LinearDNA-based COVID-19 vaccine candidate and other therapeutic candidates in the Company’s pipeline.
Recently, Applied DNA announced the successful administration and expression of a lipid nanoparticle-encapsulated (LNP) LinearDNA construct in mice via routine intramuscular (IM) injection. Based on this positive data, the Company is currently advancing several LNP LinearDNA vaccine designs that will be utilized in upcoming preclinical animal studies. Data generated by these preclinical animal studies will advance the LinearDNA platform toward the commercialization of LNP-LinearDNA vaccines for both prophylactic and therapeutic applications and will inform the final design of the Company’s LNP-LinearDNA canine cancer vaccine candidate that is currently slated to begin an initial clinical trial during 1H calendar 2023.
"The Agreement is an opportunity to expand our work with Dr. Diel and his talented team to accelerate the application of the LinearDNA platform to the animal health market," stated Dr. James A Hayward, president and CEO of Applied DNA and LineaRx. "Veterinary DNA vaccines present an attractive opportunity for us, and these animal studies should generate additional key validation data for our platform relevant to veterinary health. There is a continuing need for better veterinary therapies and we believe an LNP-LinearDNA product has the strong potential to offer enhanced ease of administration and improved clinical outcomes."
Dr. Diel said, "Vaccinology research and clinical trials are crucial to developing new prevention strategies that could have transformative applications in animal health. This partnership will help to advance research and development of novel vaccine candidates for emerging infectious diseases in ways that can benefit us all, including human and animal patients."
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using PCR to enable both the production and detection of DNA, we operate in three primary business markets: (i) the manufacture of DNA for use in nucleic acid-based therapeutics; (ii) the detection of DNA in molecular diagnostics testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.
Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under the ticker symbol ‘APDN,’ and its publicly traded warrants are listed on OTC under the ticker symbol ‘APPDW.’
The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to, its history of net losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA's or its partner's therapeutic candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration (FDA), United State Department of Agriculture (USDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final or conditional approval from the FDA, USDA or equivalent foreign regulatory agencies, the unknown outcome of any applications or requests to FDA, USDA or equivalent foreign regulatory agencies, whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials, the unknown ability to manufacture the therapeutic grade DNA in large quantities, the fact that there has never been a commercial drug product utilizing PCR-produced DNA technology approved for therapeutic use, and various other factors detailed from time to time in Applied DNA's SEC reports and filings, including our Annual Report on Form 10-K filed on December 9, 2021, its Quarterly Report on Form 10-Q filed on February 10, 2022 and May 12, 2022, and August 11, 2022, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005487/en/
Investor Relations: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com Program: Brian Viscount, 631-240-8877, brian.viscount@adnas.com Web: www.adnas.com Twitter: @APDN
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that Mr. Craig Loverock has joined the Company as Chief Financial Officer. Mr. Loverock is replacing Mr. Lachlan McLeod, who has been the acting CFO following the transition from Lions Bay Mining Inc. to BioVaxys in October 2020. Mr. McLeod will be resuming his full-time duties with Fehr & Associates CPA.
It is hard to get excited after looking at A. O. Smith's (NYSE:AOS) recent performance, when its stock has declined...
Regeneron's Eylea eye-disorder drug faces competitive pressure on multiple fronts. New data could cement its dominance.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that the manuscript "Lysergic Acid Diethylamide-Assisted Therapy In Patients With Anxiety With And Without A Life-Threatening Illness A Randomized, Double-Blind, Placebo-Controlled Phase II Study," has been published in the peer-reviewed scientific journal Biological Psychiatry. The paper expa
FDA approves AstraZeneca's (AZN) Imfinzi combination for advanced metastatic biliary tract cancer and grants Breakthrough Therapy Designation to Pfizer's (PFE) Group B Streptococcus (GBS) vaccine.
For a very long time, Botox was synonymous with the facial injections industry — the drug made by pharma company Allergan was approved for cosmetic use in 2002 and has since become widely used as an anti-wrinkle cosmetics treatment. Botox's dominance of the anti-wrinkle market slowly started to shift with the emergence of new products on the scene. In 2019, the Federal Drug Administration (FDA) approved the Jeuveau injectable serum made by beauty company Evolus .
Moderna stock has moved entirely on the perceived fortunes of its Covid-19 vaccine. Now, the company and analysts say, investors should look deeper into the pipeline.
Amylyx Pharmaceuticals Inc. shares were riding high in the first few hours of trading following a key FDA advisory committee's positive vote on its first drug, despite the unusual caveats that accompanied the vote.
Studies "support aflibercept 8 mg as a potential new standard-of-care," Regeneron Pharmaceuticals said. Regeneron stock leapt in huge volume.
An emerging crop of drug developers is using artificial intelligence, machine learning, and sometimes supercomputers to design safer and more effective drugs. The latest update from Relay Therapeutics provides early validation for a technology-enabled approach. At the very least, the preliminary data published ahead of an important scientific meeting shows the promise of the company's unique strategy to design more selective drug candidates.
Amgen's biosimilar drug is close to stealing away sales from AstraZeneca's rare disease drug called Soliris.
Regeneron (REGN) stock jumps as aflibercept 8 mg with 12- and 16-week dosing regimens in patients with DME and wAMD meet primary goals.
(Bloomberg) -- There’s a new indicator that forecasters are using to predict how much rain inland farms like the US Corn Belt will get: Salt.Most Read from BloombergCharles Becomes King as the Face of a Nation ChangesQueen Elizabeth’s Doctors Are Concerned for Her HealthQueen Elizabeth II, Britain’s Longest-Reigning Monarch, Dies at 96Most-Accurate US Artillery Shell Is Added to Ukraine’s ArmsApple’s iPhone 14 Offers Camera Upgrades, Satellite FeatureBrinier water on the surface of the ocean can
Scientists have discovered a glitch in our DNA that may have helped set the minds of our ancestors apart from those of Neanderthals and other extinct relatives. The mutation, which arose in the past few hundred thousand years, spurs the development of more neurons in the part of the brain that we use for our most complex forms of thought, according to a new study published in Science on Thursday. Sign up for The Morning newsletter from the New York Times “What we found is one gene that certainly
Mako Mining Corp. (TSX-V: MKO) (OTCQX: MAKOF) ("Mako" or the "Company") is pleased to report additional results from its recent definition and expansion drilling program at the Las Conchitas area on its wholly-owned San Albino-Murra property. The Las Conchitas area is located immediately south of the San Albino Mine which is currently in commercial production, and north of the historical El Golfo Mine located within the contiguous El Jicaro Concession.
The drugmaker's shares are skyrocketing in response to a positive advisory committee vote for its amyotrophic lateral sclerosis (ALS) drug candidate AMX0035. Specifically, a panel of experts assembled by the Food and Drug Administration (FDA) reportedly voted seven to two in favor of the available evidence supporting the drug's use as a treatment for ALS. ALS is a progressive neurodegenerative disorder that results in the loss of motor control.
Northrop Grumman CEO Kathy Warden joins 'Influencers with Andy Serwer' to discuss the company’s space business.
Analysts say the drug, from Revance Therapeutics, poses a threat to the market-dominating antiwrinkle treatment because it promises to last longer.